Manufacturer of Controlled Substances; Notice of Registration; Agilent Technologies, 64019 [2013-25078]

Download as PDF Federal Register / Vol. 78, No. 207 / Friday, October 25, 2013 / Notices renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the following basic classes of controlled substances: Drug Schedule Methylphenidate (1724) ................ Methadone (9250) ........................ Methadone Intermediate (9254) ... Tapentadol (9780) ........................ II II II II The company plans to manufacture the listed controlled substances in bulk for sale to its customers and formulation into finished pharmaceuticals. In reference to Methadone Intermediate (9254) the company plans to produce Methadone HCL active pharmaceutical ingredients (APIs) for sale to its customers. No comments or objections have been received. DEA has considered the factors in 21 U.S.C. 823(a) and determined that the registration of Boehringer Ingelheim Chemicals, Inc., to manufacture the listed basic classes of controlled substances is consistent with the public interest at this time. DEA has investigated Boehringer Ingelheim Chemicals, Inc., to ensure that the company’s registration is consistent with the public interest. The investigation has included inspection and testing of the company’s physical security systems; verification of the company’s compliance with state and local laws; and a review of the company’s background and history. Therefore, pursuant to 21 U.S.C. 823(a), and in accordance with 21 CFR 1301.33, the above named company is granted registration as a bulk manufacturer of the basic classes of controlled substances listed. Dated: October, 16 2013. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. Drug Enforcement Administration emcdonald on DSK67QTVN1PROD with NOTICES Manufacturer of Controlled Substances, Notice of Registration, Austin Pharma, LLC. By Notice dated May 14, 2013, and published in the Federal Register on May 22, 2013, 78 FR 30332, Austin Pharma, LLC., 811 Paloma Drive, Suite C, Round Rock, Texas 78665–2402, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk Jkt 232001 Dated: October 10, 2013. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. DEPARTMENT OF JUSTICE [FR Doc. 2013–25072 Filed 10–24–13; 8:45 am] BILLING CODE 4410–09–P Manufacturer of Controlled Substances; Notice of Registration; Agilent Technologies DEPARTMENT OF JUSTICE 18:57 Oct 24, 2013 The company plans to manufacture small quantities of the listed controlled substances for use in diagnostic products. No comments or objections have been received. DEA has considered the factors in 21 U.S.C. 823(a) and determined that the registration of Agilent Technologies to manufacture the listed basic classes of controlled substances is consistent with the public interest at this time. DEA has investigated Agilent Technologies to ensure that the company’s registration is consistent with the public interest. The investigation has included inspection and testing of the company’s physical security systems, verification of the company’s compliance with state and local laws, and a review of the company’s background and history. Therefore, pursuant to 21 U.S.C. 823(a), and in accordance with 21 CFR 1301.33, the above named company is granted registration as a bulk manufacturer of the basic classes of controlled substances listed. Drug Enforcement Administration BILLING CODE 4410–09–P VerDate Mar<15>2010 manufacturer of Tetrahydrocannabinols (7370), a basic class of controlled substance listed in schedule I. The company plans to bulk manufacture a synthetic Tetrahydrocannabinol. No other activity for this drug code is authorized for this registration. On August 9, 2013, Austin Pharma, LLC., withdrew their request for the addition of marihuana (7360) to their registration. No comments or objections have been received. DEA has considered the factors in 21 U.S.C. 823(a) and determined that the registration of Austin Pharma, LLC., to manufacture the listed basic class of controlled substance is consistent with the public interest at this time. DEA has investigated Austin Pharma, LLC., to ensure that the company’s registration is consistent with the public interest. The investigation has included inspection and testing of the company’s physical security systems, verification of the company’s compliance with state and local laws, and a review of the company’s background and history. Therefore, pursuant to 21 U.S.C. 823, and in accordance with 21 CFR 1301.33, the above named company is granted registration as a bulk manufacturer of the basic class of controlled substance listed. DEPARTMENT OF JUSTICE [FR Doc. 2013–25096 Filed 10–24–13; 8:45 am] 64019 By Notice dated May 24, 2013, and published in the Federal Register on June 4, 2013, 78 FR 33441, Agilent Technologies, 25200 Commercentre Drive, Lake Forest, California 92630– 8810, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the following basic classes of controlled substances: Drug Schedule 1-Piperidinocyclohexanecarbonitrile (8603). Benzoylecgonine (9180) ............... PO 00000 Frm 00061 Fmt 4703 Sfmt 4703 II II Dated: October 10, 2013. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. 2013–25078 Filed 10–24–13; 8:45 am] BILLING CODE 4410–09–P Drug Enforcement Administration Manufacturer of Controlled Substances, Notice of Registration, Penick Corporation By Notice dated May 24, 2013, and published in the Federal Register on June 4, 2013, 78 FR 33441, Penick Corporation, 33 Industrial Park Road, Pennsville, New Jersey 08070, made application to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of Opium Tincture (9630), a basic class of controlled substance listed in schedule II. The company plans to manufacture the listed controlled substance, as bulk intermediates for distribution to its customers. No comments or objections have been received. DEA has considered the factors in 21 U.S.C. 823(a) and determined that the registration of Penick Corporation to manufacture the listed basic class of controlled substance is consistent with the public interest at this time. DEA has investigated Penick Corporation to ensure that the company’s registration is consistent with the public interest. The E:\FR\FM\25OCN1.SGM 25OCN1

Agencies

[Federal Register Volume 78, Number 207 (Friday, October 25, 2013)]
[Notices]
[Page 64019]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2013-25078]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Manufacturer of Controlled Substances; Notice of Registration; 
Agilent Technologies

    By Notice dated May 24, 2013, and published in the Federal Register 
on June 4, 2013, 78 FR 33441, Agilent Technologies, 25200 Commercentre 
Drive, Lake Forest, California 92630-8810, made application by renewal 
to the Drug Enforcement Administration (DEA) to be registered as a bulk 
manufacturer of the following basic classes of controlled substances:

------------------------------------------------------------------------
                    Drug                               Schedule
------------------------------------------------------------------------
1-Piperidinocyclohexane-carbonitrile (8603)  II
Benzoylecgonine (9180).....................  II
------------------------------------------------------------------------

    The company plans to manufacture small quantities of the listed 
controlled substances for use in diagnostic products.
    No comments or objections have been received. DEA has considered 
the factors in 21 U.S.C. 823(a) and determined that the registration of 
Agilent Technologies to manufacture the listed basic classes of 
controlled substances is consistent with the public interest at this 
time. DEA has investigated Agilent Technologies to ensure that the 
company's registration is consistent with the public interest. The 
investigation has included inspection and testing of the company's 
physical security systems, verification of the company's compliance 
with state and local laws, and a review of the company's background and 
history. Therefore, pursuant to 21 U.S.C. 823(a), and in accordance 
with 21 CFR 1301.33, the above named company is granted registration as 
a bulk manufacturer of the basic classes of controlled substances 
listed.

     Dated: October 10, 2013.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
[FR Doc. 2013-25078 Filed 10-24-13; 8:45 am]
BILLING CODE 4410-09-P